Overview
Sonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectations
Net loss per share decreases 46% for fiscal Q2 compared to last year
U.S. revenue increases 115% for fiscal Q2, driven by OTC product sales
Outlook
Company expects positive growth trajectory with increasing product adoption
Result Drivers
U.S. SALES GROWTH - Revenue in the U.S. increased 115% due to higher sales of OTC products and increased distributor sales
NEW PRODUCT LAUNCHES - Launch of HOCl-based diaper rash products and other new products contributed to revenue growth
REGULATORY MILESTONES - Key regulatory clearances, including FDA registration, supported growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $5.60 mln | $4.26 mln (1 Analyst) |
Q2 EPS | -$0.32 | ||
Q2 Net Income | -$500,000 | ||
Q2 EBITDA | -$200,000 | ||
Q2 Gross Profit | $2.10 mln | ||
Q2 Operating Expenses | $2.50 mln |
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 74.5% above its November 3 closing price of $3.78
Press Release: ID:nACSQC7GQa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)